Well today I sold my shares in Medical Developments International. It was a borderline call, as the thesis is still mostly there. However, the new piece of information was that the company gave the following guidance:
read moreHere is the updated hypothetical ethical share portfolio. I'm trying to make my reporting of this hypothetical ethical share portfolio as transparent as possible: suggestions are welcome. I'm thinking of adjusting the buy price to reflect dividends received.
read moreThis is just a short note on IMF Australia (ASX:IMF), [name changing to Bentham IMF] the litigation funders. IMF have recently expanded into the USA, and they had quite low profits in FY 2013. Furthermore, they have just diluted shareholders at a share price of $1.70, and convertible notes are being redeemed at $1.65 per share.
read moreIt has been announced this morning that Medical Developments International has received FDA approval for its Space Chamber asthma spacers. Since I bought shares, the company has moved forward with a number of its initiatives (selling asthma devices into the USA is just one of them). Importantly, the application for marketing approval of Penthrox in Europe has been accepted for consideration. These are both positives. However, the company has also reported reduced sales of Penthrox in Australia, meaning that the shares are no more attractive now than when I bought them, in my opinion. The current price is $1.38 (only slightly above my average entry price).
read moreI bought shares in Fiducian Portfolio Services a couple of weeks ago because, based on a conservative discounted cashflow valuation, I believed their shares were undervalued. I'm now adding Fiducian Portfolio Services to the Hypothetical Sample Ethical Portfolio, with the caveat that 10% of the profits of Fiducian should be donated to charity, because Fiducian is not a particularly ethical investment. The hidden report contains a discussion of the ethics of investing in Fiducian.
read moreThis sample portfolio is meant to represent a hypothetical ethical portfolio, so it is diversified across a number of industries. The purpose of this portfolio is not to suggest it is the best portfolio. It certainly isn't my portfolio. This portfolio is an experiment.
read more1300 Smiles achieves excellent returns on investment and the Managing Director, Dr Daryl Holmes, appears to have a lot of integrity. He proudly supports charity and owns over 60% of the company, which he founded. The company boasts impressive earnings growth since listing in 2005. The company is providing low cost dental care. The business of the company is to help dentists run more more profitable businesses by allowing them to focus on what they do best: treat patients.
read moreOne of my favourite small cap companies, Beyond International (ASX: BYI) has announced a joint venture with Seven Network, owned by Seven West Media (ASX: SWM). Beyond Productions will join forces with Seven to create new programs for the North American market.The JV will be called 7Beyond and is based in Los Angeles.
read more